Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + thymosin α1
- Development stage
- Unknown
- Lead developer
- The First Hospital of Jilin University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Entecavir + thymosin α1 is an investigational combination regimen being studied for the treatment of HBeAg-positive chronic hepatitis B. The regimen pairs entecavir, a nucleoside analogue antiviral that inhibits hepatitis B virus (HBV) DNA polymerase (reverse transcriptase), with thymosin α1, a synthetic 28-amino acid peptide that acts as a biological immunomodulator. Entecavir works by suppressing HBV viral replication, while thymosin α1 enhances the host immune response by promoting T-cell maturation and activation. This combination approach is hypothesized to provide a more effective therapeutic outcome, including higher rates of HBeAg seroconversion and viral clearance, compared to entecavir monotherapy. The regimen has been primarily evaluated in investigator-initiated clinical trials, such as those led by the First Hospital of Jilin University.
- Brand names
- ZadaxinBaraclude
- Other names
- entecavir + thymosin alpha-1entecavir combined with thymosin alpha-1entecavir combined with thymosin α1
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptaseTLR (Toll-like receptors)POLE (DNA polymerase epsilon)
Beyond the preview
Go deeper on entecavir + thymosin α1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + thymosin α1.